Liarozol

Liarozol
Nazivi
	IUPAC naziv 6-[(3-hlorofenil)-imidazol-1-ilmetil]-1H-benzimidazol
Identifikacija
CAS broj	115575-11-6;
3D model (Jmol)	interaktivna slika;
ChemSpider	54664;
IUPHAR/BPS	5210;
PubChem C ID	60652;
	SMILES C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4; ; ; ; ; ;
Svojstva
Hemijska formula	C17H13ClN4
Molarna masa	308,77 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	Reference infokutije

Liarozol je jedinjenje koje inhibira metabolizam retinoinske kiseline.^[3]

Sinteza

Sintezy liarozola

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Vahlquist, A; Blockhuys, S; Steijlen, P; Van Rossem, K; Didona, B; Blanco, D; Traupe, H (2013). „Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: Results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial”. The British journal of dermatology. 170 (1): n/a. PMID 24102348. doi:10.1111/bjd.12626.